Mark W. Ward, BA

Uptake of the new oral agents gilenya and Ampyra may be expected to increase rapidly in the future, if for largely different reasons.

The antihyperglycemic therapeutic class will continue to be a major contributor to prescription drug trends in 2011 and beyond.